Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 5,400 Shares

Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 5,400 shares of the stock in a transaction on Thursday, July 20th. The shares were purchased at an average price of $6.46 per share, with a total value of $34,884.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $19,825,423.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, August 17th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The stock was acquired at an average cost of $5.96 per share, with a total value of $298,000.00.
  • On Wednesday, August 16th, Phillip Md Et Al Frost acquired 40,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.04 per share, for a total transaction of $241,600.00.
  • On Tuesday, August 15th, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.08 per share, for a total transaction of $152,000.00.
  • On Monday, August 14th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.15 per share, for a total transaction of $61,500.00.
  • On Friday, August 11th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.19 per share, for a total transaction of $61,900.00.
  • On Thursday, August 10th, Phillip Md Et Al Frost acquired 39,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.23 per share, for a total transaction of $242,970.00.
  • On Wednesday, August 9th, Phillip Md Et Al Frost purchased 18,000 shares of Opko Health stock. The stock was bought at an average cost of $6.35 per share, for a total transaction of $114,300.00.
  • On Tuesday, August 8th, Phillip Md Et Al Frost purchased 5,000 shares of Opko Health stock. The stock was bought at an average cost of $6.05 per share, for a total transaction of $30,250.00.
  • On Wednesday, August 2nd, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The stock was purchased at an average price of $6.15 per share, for a total transaction of $153,750.00.
  • On Tuesday, August 1st, Phillip Md Et Al Frost purchased 46,600 shares of Opko Health stock. The shares were bought at an average price of $6.25 per share, for a total transaction of $291,250.00.

Opko Health, Inc. (NASDAQ OPK) traded up 4.08% during midday trading on Friday, hitting $6.12. The company had a trading volume of 6,288,570 shares. The stock’s market capitalization is $3.42 billion. Opko Health, Inc. has a 52 week low of $5.85 and a 52 week high of $12.15. The stock has a 50 day moving average price of $6.27 and a 200-day moving average price of $7.19.

Opko Health (NASDAQ:OPK) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The business had revenue of $314.20 million during the quarter, compared to analysts’ expectations of $322.64 million. During the same quarter in the prior year, the firm earned $0.02 earnings per share. The business’s revenue was down 12.0% compared to the same quarter last year. On average, equities analysts predict that Opko Health, Inc. will post ($0.20) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.com-unik.info/2017/08/19/opko-health-inc-nasdaqopk-ceo-acquires-34884-00-in-stock-updated-updated-updated.html.

Several research analysts recently weighed in on OPK shares. Jefferies Group LLC restated a “hold” rating and issued a $8.00 price objective on shares of Opko Health in a research report on Monday, June 12th. Cantor Fitzgerald began coverage on shares of Opko Health in a research report on Thursday. They issued an “overweight” rating and a $20.00 price objective on the stock. Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research note on Friday, July 21st. Barrington Research increased their price objective on Opko Health to $11.00 and gave the company an “outperform” rating in a research note on Tuesday, July 18th. Finally, BidaskClub raised Opko Health from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $15.28.

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new stake in Opko Health during the fourth quarter valued at about $105,000. Comerica Bank purchased a new position in Opko Health during the fourth quarter valued at approximately $117,000. Timber Hill LLC purchased a new position in Opko Health during the first quarter valued at approximately $114,000. World Asset Management Inc raised its position in Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,900 shares in the last quarter. Finally, IFC Holdings Incorporated FL raised its position in Opko Health by 15.9% in the first quarter. IFC Holdings Incorporated FL now owns 15,339 shares of the biotechnology company’s stock worth $122,000 after buying an additional 2,100 shares during the period. 22.94% of the stock is owned by hedge funds and other institutional investors.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

What are top analysts saying about Opko Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Opko Health Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit